Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00520208
Other study ID # INNO-507-P2
Secondary ID
Status Completed
Phase Phase 2
First received August 21, 2007
Last updated February 11, 2013
Start date September 2007
Est. completion date January 2013

Study information

Verified date February 2013
Source CytRx
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

This is a Phase II, open-label, non-randomized study to evaluate the safety, efficacy, and pharmacokinetics of tamibarotene in adult patients with relapsed or refractory acute promyelocytic leukemia (APL) following treatment with all-trans-retinoic acid (ATRA) and arsenic trioxide (ATO). Patients must have received and failed therapy with ATRA and ATO. Treatment may have been administered either as combination therapy or sequentially as single agents. Patients who are intolerant to either drug are eligible for this study.


Recruitment information / eligibility

Status Completed
Enrollment 15
Est. completion date January 2013
Est. primary completion date December 2012
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Patients must meet all of the following criteria for admission into the study:

1. Have a diagnosis of either relapsed and/or refractory APL:

- Refractory disease is defined as a confirmed diagnosis of APL and a myeloblast plus promyelocyte count of > 10% in the bone marrow in patients who have failed to respond to induction therapy in the first or second line setting. Induction therapy must have included ATRA- and ATO-based therapy given either sequentially or in combination.

- Relapsed disease is defined as a confirmed diagnosis of APL and a myeloblast plus promyelocyte count of > 10% in the bone marrow following a documented complete remission or positive RT-PCR assay for PML/RAR-a in two consecutive tests separated by at least one month, after treatment with ATRA- and ATO-based therapy given either sequentially or in combination.

2. Confirmation of diagnosis and relapsed/refractory APL must be obtained in blood or bone marrow mononuclear cells by at least one of the following methods:

- Conventional cytogenetics showing the translocation t(15:17),

- Positive RT-PCR assay for PML/RAR-a, or

- Fluorescence in situ hybridization (FISH) analysis showing evidence of the PML/RAR-a translocation.

3. Patients must have received and failed therapy with ATRA and ATO either within the same or separate induction/consolidation schedule(s). Treatment must have been administered for a minimum of 28 days for each agent. Treatment may have been administered either as combination therapy or sequentially as single agents. Patients who failed to complete a course of induction/consolidation therapy, as specified, due to drug intolerance are eligible for the study.

4. Patients in whom ATO is contraindicated (for example due to congenital long QT syndrome) are eligible for inclusion on study if they have received and failed ATRA therapy as defined in (3).

5. Be able to provide written informed consent prior to enrollment into the study.

6. Be = 18 years old.

7. Have an Eastern Cooperative Oncology Group (ECOG) Performance Status of = 2.

8. Have an estimated life expectancy of = 12 weeks.

9. Be male or a non-pregnant, non-lactating female. Fertile patients must agree to use an effective barrier method of contraception (e.g., latex condom, diaphragm, or cervical cap) to avoid pregnancy while on therapy and for 90 days following the discontinuation of the study drug. [In countries where double barrier contraception is required by Regulatory Authorities, patients who are fertile must agree to use 2 forms of barrier method contraception (e.g., latex condom AND a diaphragm or cervical cap) while on therapy and for 90 days following the discontinuation of the study drug.]

A non-fertile female is defined as:

- Postmenopausal (amenorrheic for = 12 months)

- Undergone a complete oophorectomy or hysterectomy.

10. Have a negative serum or urine pregnancy test within 10 days prior to the first dose of study drug (if patient is a female of childbearing potential).

11. Have adequate organ function.

Patients who meet any of the following criteria will be excluded from study admission:

1. Extramedullary leukemia.

2. Patients on a vitamin A preparation or patients with hypervitaminosis A.

3. Have received cytotoxic therapy = 2 weeks from the start of therapy. If the patient needs these agents due to urgent medical care within 2 weeks prior to starting tamibarotene, a waiver may be granted by the INNOVIVE Medical Monitor.

4. Have a history of myelodysplastic syndromes (MDS).

5. Have impaired cardiac function or clinically significant heart disease including:

- Myocardial infarction within 3 months, unstable angina pectoris, congenital long QT syndrome and clinically significant resting bradycardia (< 50 beats per minute), uncontrolled congestive heart failure, uncontrolled hypertension, history of labile hypertension, or history of poor compliance with antihypertensive medication.

6. Have an active, uncontrolled systemic infection considered opportunistic, life-threatening, or clinically significant at the time of treatment.

7. Have clinically significant acute or chronic liver or renal disease considered unrelated to leukemia.

8. Have uncontrolled hyperlipidemia.

9. Have uncontrolled or poorly controlled diabetes mellitus.

10. Have impaired gastrointestinal function that may significantly alter drug absorption (e.g., uncontrolled vomiting, ulcerative colitis, malabsorption, or small bowel resection).

11. Are pregnant or lactating.

12. Have psychiatric disorder(s) that would interfere with consent, study participation, or follow-up.

13. Have not recovered from acute toxicities of all previous therapy prior to enrollment.

14. Have any other severe concurrent disease and/or uncontrolled medical conditions, which, in the judgment of the investigator, could predispose patients to unacceptable safety risks or compromise compliance with the protocol.

15. Have a history of another primary malignancy that has been actively treated in the last 24 months.

16. Are unwilling or unable to comply with the protocol.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Drug:
Tamibarotene
For induction therapy, tamibarotene will be self-administered via tablets on an outpatient basis at a dose of 6 mg/m2 per day, taken orally, in two divided doses approximately one hour after breakfast and dinner. Induction therapy will continue for a maximum of 56 days until either a morphologic leukemia-free state or complete response (CR) has been achieved. For patients who achieve a CR with induction therapy, consolidation therapy will commence 4 to 8 weeks after the end of induction therapy. For patients who have a morphologic leukemia-free state after induction therapy but who fail to achieve a CR, consolidation therapy will commence 8 weeks after the end of induction therapy.

Locations

Country Name City State
United States Northwestern University Chicago Illinois
United States UT MD Anderson Cancer Center Houston Texas

Sponsors (1)

Lead Sponsor Collaborator
CytRx

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary To determine the rate of durable complete response for tamibarotene therapy when administered as a single agent to adult patients with relapsed or refractory APL. Minimum 28 days No
Secondary (1) To determine the rates of morphologic leukemia-free state, partial response, cytogenetic complete response, and molecular complete response for tamibarotene therapy in the indicated patient population. Minimum 28 days No
Secondary (2) To determine the safety profile and tolerability of tamibarotene in the indicated patient population. Up to 32 weeks Yes
Secondary (3) To determine the pharmacokinetic (PK) profile of tamibarotene when administered in the indicated patient population. One year No
See also
  Status Clinical Trial Phase
Suspended NCT04996030 - A Study for Oral SY-2101 for Participants With Acute Promyelocytic Leukemia Phase 1
Recruiting NCT02899169 - Treatment of Non-high-risk Acute Promyelocytic Leukemia (APL) With Realgar-Indigo Naturalis Formula (RIF) Phase 3
Terminated NCT00852709 - Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute Leukemias Phase 1
Recruiting NCT04793919 - Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia Phase 2
Recruiting NCT02938858 - French Registry of First-line Treatment of Acute Promyelocytic Leukemia N/A
Recruiting NCT02991066 - Role of Microparticles in the Coagulopathy of Acute Promyelocytic Leukemia
Terminated NCT00985530 - Tamibarotene and Arsenic Trioxide for Relapsed Acute Promyelocytic Leukemia Phase 1
Withdrawn NCT00670150 - New Retinoid Agent Combined With Arsenic Trioxide for Untreated Acute Promyelocytic Leukemia Phase 2
Recruiting NCT01064570 - AIDA 2000 Guidelines Phase 2
Completed NCT01472107 - Study on Number and Outcome of Pregnancy in Acute Promielocitic Leukaemia (APL) Patients Treated With Chemotherapy
Active, not recruiting NCT03096496 - Long-term QoL in Acute Promyelocytic Leukemia Treated With ATO or Standard Chemotherapy
Completed NCT00465933 - Treatment of Acute Promyelocytic Leukemia With All-Trans Retinoic Acid (ATRA) and Idarubicin (AIDA) Phase 4
Active, not recruiting NCT02688140 - Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia Phase 3
Active, not recruiting NCT01987297 - Combined Retinoic Acid,Arsenic Trioxide and Chemo for Newly-diagnosed APL Phase 4
Terminated NCT00907582 - ASCT for Relapsed APL After Molecular Remission Phase 2
Recruiting NCT00517712 - Single Agent Arsenic Trioxide in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia Phase 2/Phase 3
Completed NCT01902329 - A Safety Study of SGN-CD33A in AML Patients Phase 1
Completed NCT01404949 - Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy Phase 2
Completed NCT00504764 - Treatment of Relapsed Promyelocytic Leukemia With Arsenic Trioxide (ATO) Phase 4
Completed NCT00408278 - Treatment of Newly Diagnosed Patients With Acute Promyelocytic Leukemia (PETHEMA LPA 2005) Phase 4